Tarsus Pharmaceuticals
(NASDAQ) TARS
Tarsus Pharmaceuticals Financials at a Glance
Market Cap
$2.98B
Revenue (TTM)
$451.36M
Net Income (TTM)
$66.42M
EPS (TTM)
$-1.61
P/E Ratio
-43.56
Dividend
$0.00
Beta (Volatility)
0.88 (Low)
Dividend
$0.00
Beta (Volatility)
0.88 (Low)
Price
$69.99
Volume
11,094
Open
$69.66
Price
$69.99
Volume
11,094
Open
$69.66
Previous Close
$69.99
Daily Range
$69.50 - $71.24
52-Week Range
$38.51 - $85.25
Dividend
$0.00
Beta (Volatility)
0.88 (Low)
Price
$69.99
Volume
11,094
Open
$69.66
Previous Close
$69.99
Daily Range
$69.50 - $71.24
52-Week Range
$38.51 - $85.25
TARS News
TARS: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Tarsus Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareEmployees
370
CEO
Bobak Azamian, MD, PhD
Website
tarsusrx.comHeadquarters
Irvine, CA 92618, US
TARS Financials
Key Financial Metrics (TTM)
Gross Margin
90%
Operating Margin
-16%
Net Income Margin
-15%
Return on Equity
-23%
Return on Capital
-17%
Return on Assets
-12%
Earnings Yield
-2.30%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.98B
Shares Outstanding
42.56M
Volume
11.09K
Short Interest
0.00%
Avg. Volume
575.71K
Financials (TTM)
Gross Profit
$420.68M
Operating Income
$70.97M
EBITDA
$53.61M
Operating Cash Flow
$12.45M
Capital Expenditure
$9.86M
Free Cash Flow
$22.31M
Cash & ST Invst.
$417.27M
Total Debt
$93.64M
Tarsus Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$151.67M
+128.4%
Gross Profit
$140.74M
+128.9%
Gross Margin
92.80%
N/A
Market Cap
$2.98B
N/A
Market Cap/Employee
$9.24M
N/A
Employees
323
N/A
Net Income
$8.37M
+63.8%
EBITDA
$3.66M
+82.0%
Quarterly Fundamentals
Net Cash
$323.63M
+47.8%
Accounts Receivable
$87.11M
+81.3%
Inventory
$4.37M
+66.9%
Long Term Debt
$93.64M
+30.3%
Short Term Debt
$0.00
-100.0%
Return on Assets
-11.81%
N/A
Return on Invested Capital
-16.64%
N/A
Free Cash Flow
$12.97M
+147.6%
Operating Cash Flow
$19.33M
+187.1%